<DOC>
	<DOCNO>NCT00842400</DOCNO>
	<brief_summary>The purpose study : - Find much study drug blood healthy subject take multiple dos VI-0521 , metformin sitagliptan . - Determine effect probenecid amount VI-0521 blood healthy subject take multiple dos . - Find much topiramate semen healthy male subject take multiple dos .</brief_summary>
	<brief_title>A Drug Interaction Study VI-0521 With Metformin , Sitagliptan Probenecid Healthy Subjects .</brief_title>
	<detailed_description>This trial open-label , non-randomized , one-sequence crossover study . All subject receive oral dose metformin 500 mg tablet twice daily Days 1 5 Days 30 34 ; oral dose sitagliptin 100 mg tablet daily Days 6 10 Days 35 39 single oral dose VI-0521 ( phentermine/topiramate ) capsule daily morning 3.75/23 mg 2 day ( Days 11-12 ) , 7.5/46 mg 3 day ( Days 13-15 ) , 11.25/69 mg 3 day ( Days 16-18 ) 15/92 mg 21 day ( Days 19-39 ) plus single oral dose 2 g ( four 500 mg ) probenecid tablet Day 29 . Subjects remain site duration study ( Day -1 Day 40 ) . Blood sample determination metformin concentration plasma collect 0 ( pre-dose ) , 1 , 2 , 3 , 4 , 6 , 8 12 hour morning administration metformin metformin plus VI-0521 Days 5 34 . Blood sample determination sitagliptin concentration plasma collect 0 ( pre-dose ) , 1 , 2 , 3 , 4 , 5 , 7 , 10 , 16 24 hour administration sitagliptin sitagliptin plus VI-0521 Days 10 39 . Blood sample determination phentermine topiramate concentration plasma collect 0 ( pre-dose ) , 1 , 2 , 3 , 4 , 5 , 7 , 10 , 16 24 hour administration investigational product ( ) Days 28 , 29 , 34 39 . Pre-dose blood sample determination investigational drug concentration plasma take morning Days 4 33 metformin ; Days 9 38 sitagliptin Days 27 , 33 38 phentermine topiramate . Semen sample determination topiramate concentration collect Day 28 five seven hour VI-0521 administration 8 male non-vasectomized subject obtain least 6 evaluable subject . The primary endpoint study PK parameter AUC0-Ï„ Cmax phentermine , topiramate , sitagliptin metformin.The secondary endpoint topiramate concentration semen .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<criteria>The study population consist adult healthy male female , 1945 year age ; inclusive medically healthy clinically significant screen result . Main exclusion criterion include history presence significant cardiovascular , neurological , hematological , psychiatric , hepatic , gastrointestinal , pulmonary , endocrine , immunologic renal disease condition know interfere absorption , distribution , metabolism , excretion drug place subject increase risk determine Investigator ; clinically significant laboratory abnormality judge Investigator ; history glaucoma , increase intraocular pressure , medication treat increase intraocular pressure ; presence cholelithiasis cholecystitis within last 6 month surgically treat cholecystectomy ; history cardiovascular cerebrovascular event ; active malignancy except basal cell carcinoma ; systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 95 mm Hg screening checkin ( Two rechecks allow ) ; positive drug/alcohol test screen check ; blood donation significant blood loss within 56 day dose ; plasma donation within 7 day dose . In female subject , positive pregnancy test screen checkin exclusionary .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Obesity</keyword>
</DOC>